论文部分内容阅读
目的比较CCB菲洛地平和ARB替米沙坦对2型糖尿病合并高血压患者血压以及代谢指标的控制效果。方法本试验共入选45例2型糖尿病合并高血压的患者,随机分为两组,A组接受罗格列酮(RSG)4 mg+替米沙坦(Telm)80 mg;B组接受罗格列酮(RSG)4 mg+菲洛地平(Felo- dipine)5 mg,所有患者同时接受二甲双胍治疗(metformin),但未接受其他降压药物治疗。结果6个月治疗后,两组血压水平均有明显下降(A组下降14.6%,B组下降14.8%),同时血糖和胰岛素抵抗均得到一定改善。A组的血糖、三酰甘油水平和HbA1c以及HOMA指数较B组低。结论在2型糖尿病合并高血压患者,RSG 4 mg+Telm 80 mg较RSG 4 mg+Felo 5 mg更能改善2型糖尿病的代谢障碍,对血压和胰岛素抵抗的良好控制使替米沙坦更适合于代谢综合征的治疗。
Objective To compare the control effects of CCB filipin and ARB telmisartan on blood pressure and metabolic parameters in type 2 diabetic patients with hypertension. Methods A total of 45 patients with type 2 diabetes mellitus and hypertension were randomly divided into two groups. Group A received rosiglitazone (RSG) 4 mg + telmisartan 80 mg; group B received rosiglitazone (RSG) 4 mg and Felo dipine 5 mg. All patients received metformin concurrently but did not receive other antihypertensive drugs. Results After 6 months of treatment, the blood pressure levels of both groups were significantly decreased (A group decreased 14.6%, B group decreased 14.8%), while blood glucose and insulin resistance were improved. A group of blood glucose, triglyceride levels and HbA1c and HOMA index lower than the B group. CONCLUSIONS: RSG 4 mg + Telm 80 mg improves the metabolic disorder of type 2 diabetes mellitus compared with RSG 4 mg + Felo 5 mg in patients with type 2 diabetes mellitus and hypertension, and good control of blood pressure and insulin resistance makes telmisartan more suitable In the treatment of metabolic syndrome.